Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis; A Nonrandomized Controlled Trial
Sponsor: Peking University First Hospital
Terminated
Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.
Other terminated trials from Peking University First Hospital
A NA clinical study on Palmoplantar Pustulosis, this trial is terminated or withdrawn. The trial is conducted by Peking University First Hospital and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Mar 2026 — Present [monthly]
Terminated NA
Status: Not Yet Recruiting → Terminated
-
Jun 2025 — Mar 2026 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University First Hospital
For direct contact, visit the study record on ClinicalTrials.gov .